Immune-based Therapies
Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma
Drugs 2021 June [Link] Wanyuan Cui, Sanjay Popat Abstract Immune checkpoint inhibitors (ICI) have shown important but variable efficacy in mesothelioma despite a lack of strong biological rationale. Initial trials assessed ICI monotherapy in patients with relapsed mesothelioma, with objective response rates (ORR) between 4.5 and 29%, median progression-free survival (PFS) between 2.5-6.2 months, and…
Read MoreNIPU: a randomised, open-label, phase II study evaluating nivolumab and ipilimumab combined with UV1 vaccination as second line treatment in patients with malignant mesothelioma
Journal of Translational Medicine 2021 May 31 [Link] Vilde Drageset Haakensen, Anna K Nowak, Espen Basmo Ellingsen, Saima Jamil Farooqi, Maria Moksnes Bjaanæs, Henrik Horndalsveen, Tine Mcculloch, Oscar Grundberg, Susana M Cedres, Åslaug Helland Abstract Background: Malignant pleural mesothelioma (MPM) is a rare and aggressive tumour. For patients with inoperable disease, few treatment options are…
Read MoreEpidemiology, diagnosis and treatment of the malignant pleural mesothelioma, a narrative review of literature
Journal of Thoracic Disease 2021 April [Link] Sven Oliver Schumann, Gregor Kocher, Fabrizio Minervini Abstract The malignant pleural mesothelioma is a very aggressive tumor which is arising from mesothelial cells and is associated with asbestos exposure. It is a heterogeneous cancer that shows a complex pattern of molecular changes, including genetic, chromosomic, and epigenetic abnormalities.…
Read MoreCAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials
Lung Cancer 2021 May 5 [Link] Navin K Chintala, David Restle, Hue Quach, Jasmeen Saini, Rebecca Bellis, Michael Offin, Jason Beattie, Prasad S Adusumilli Abstract The aim of adoptive T-cell therapy is to promote tumor-infiltrating immune cells following the transfer of either tumor-harvested or genetically engineered T lymphocytes. A new chapter in adoptive T-cell therapy…
Read MoreEmerging avenues in immunotherapy for the management of malignant pleural mesothelioma
BMC Pulmonary Medicine 2021 May 5 [Link] Steven G Gray Abstract Background: The role of immunotherapy in cancer is now well-established, and therapeutic options such as checkpoint inhibitors are increasingly being approved in many cancers such as non-small cell lung cancer (NSCLC). Malignant pleural mesothelioma (MPM) is a rare orphan disease associated with prior exposure…
Read MoreEmerging biological therapies for the treatment of malignant pleural mesothelioma
Expert Opinion on Emerging Drugs 2021 May 4 [Link] Alexander P Davis, Steven C Kao, Stephen J Clarke, Michael Boyer, Nick Pavlakis Abstract Introduction: Malignant pleural mesothelioma (MPM) has limited treatment options with minimal new therapy approvals for unresectable disease in the past 15 years. However, considerable work has occurred to develop immunotherapies and biomarker…
Read MoreP14/ARF-Positive Malignant Pleural Mesothelioma: A Phenotype With Distinct Immune Microenvironment
Frontiers in Oncology 2021 March 22 [Link] Federica Pezzuto, Francesca Lunardi, Luca Vedovelli, Francesco Fortarezza, Loredana Urso, Federica Grosso, Giovanni Luca Ceresoli, Izidor Kern, Gregor Vlacic, Eleonora Faccioli, Marco Schiavon, Dario Gregori, Federico Rea, Giulia Pasello, Fiorella Calabrese Abstract Introduction: The CDKN2A gene plays a central role in the pathogenesis of malignant pleural mesothelioma (MPM).…
Read MoreNF2 and Canonical Hippo-YAP Pathway Define Distinct Tumor Subsets Characterized by Different Immune Deficiency and Treatment Implications in Human Pleural Mesothelioma
Cancers 2021 March 29 [Link] Haitang Yang, Sean R R Hall, Beibei Sun, Liang Zhao, Yanyun Gao, Ralph A Schmid, Swee T Tan, Ren-Wang Peng, Feng Yao Abstract (1) Inactivation of the tumor suppressor NF2 is believed to play a major role in the pathogenesis of malignant pleural mesothelioma (MPM) by deregulating the Hippo-YAP signaling…
Read MoreEliminating mesothelioma by AAV-vectored, PD1-based vaccination in the tumor microenvironment
Molecular Therapy Oncolytics 2021 January 21 [Link] Zhiwu Tan, Mei Sum Chiu, Chi Wing Yan, Kwan Man, Zhiwei Chen Abstract The potency of cancer vaccines is often compromised by a variety of immunoinhibitory mechanisms, including stimulation of the programmed cell death protein 1 (PD-1)/programmed death ligand 1 (PD-L1) immune checkpoint pathway. Here, to overcome inhibition,…
Read MoreSerum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial
Lung Cancer 2021 January 14 [Link] Sharyn I Katz, Leonid Roshkovan, Ian Berger, Joseph S Friedberg, Evan W Alley, Charles B Simone 2nd, Andrew R Haas, Keith A Cengel, Daniel H Sterman, Steven M Albelda Abstract Objectives: Soluble mesothelin-related protein (SMRP) and fibulin-3 serum levels may serve as diagnostic and prognostic biomarkers of malignant pleural…
Read More